Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted) (2022 - 2025)

Silence Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.09 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 200.0% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.63, a 96.87% decrease, with the full-year FY2025 number at -$0.63, down 90.91% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.09 in Q4 2025 for Silence Therapeutics, up from -$0.15 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for SLN hit a ceiling of $0.09 in Q4 2024 and a floor of -$0.25 in Q3 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.12 across 4 years, with a median of -$0.15 in 2025.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 166.92% in 2024 and later tumbled 900.0% in 2025.
  • Tracing SLN's EPS (Weighted Average and Diluted) over 4 years: stood at -$0.16 in 2022, then rose by 13.69% to -$0.13 in 2023, then soared by 166.92% to $0.09 in 2024, then tumbled by 200.0% to -$0.09 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SLN at -$0.09 in Q4 2025, -$0.15 in Q3 2025, and -$0.19 in Q2 2025.